Krystal Biotech (KRYS) Non-Current Assets (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly Non-Current Assets of $441.0 million for Q2 2026, up 48.46% year-over-year from $297.0 million in Q2 2025, and up 16.91% on a QoQ basis from $377.2 million in Q1 2026.
Krystal Biotech (KRYS) Non-Current Assets (2016 - 2026) Analysis & Trends
Krystal Biotech has reported Non-Current Assets for 11 years, with the latest figure at $441.0 million in Q2 2026.
- Non-Current Assets for Q2 2026 came in at $441.0 million, up 48.46% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.4 billion (up 21.41% YoY), and the FY2025 annual result was $309.2 million, down 1.47% from the prior year.
- Non-Current Assets improved to $441.0 million in Q2 2026, from $377.2 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $441.0 million in Q2 2026 and troughed at $172.6 million in Q2 2022.
- A 5-year average of $257.5 million and a median of $243.0 million in 2024 frame the typical range for Non-Current Assets.
- The largest YoY upside for Non-Current Assets was 380.95% in 2022 against a maximum downside of 5.08% in 2022.
- A 5-year view of Non-Current Assets shows it stood at $174.7 million in 2022, then jumped by 31.93% to $230.4 million in 2023, then jumped by 36.17% to $313.8 million in 2024, then slipped by 1.47% to $309.2 million in 2025, then surged by 42.63% to $441.0 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $441.0 million in Q2 2026, $377.2 million in Q1 2026, and $309.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 441.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 441.00 Mn |
| Mar 31, 2026 | 377.23 Mn |
| Dec 31, 2025 | 309.19 Mn |
| Sep 30, 2025 | 314.44 Mn |
| Jun 30, 2025 | 297.05 Mn |
| Mar 31, 2025 | 307.62 Mn |
| Dec 31, 2024 | 313.79 Mn |
| Sep 30, 2024 | 269.15 Mn |
| Jun 30, 2024 | 234.89 Mn |
| Mar 31, 2024 | 251.05 Mn |
| Dec 31, 2023 | 230.45 Mn |
| Sep 30, 2023 | 208.22 Mn |
| Jun 30, 2023 | 200.02 Mn |
| Mar 31, 2023 | 176.42 Mn |
| Dec 31, 2022 | 174.67 Mn |
| Sep 30, 2022 | 178.80 Mn |
| Jun 30, 2022 | 172.55 Mn |
| Mar 31, 2022 | 178.88 Mn |
| Dec 31, 2021 | 184.03 Mn |
| Sep 30, 2021 | 105.28 Mn |